<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00139555</url>
  </required_header>
  <id_info>
    <org_study_id>CCIB002FUS16</org_study_id>
    <nct_id>NCT00139555</nct_id>
  </id_info>
  <brief_title>Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension</brief_title>
  <official_title>Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and
      mortality in patients with high blood pressure, compared to those without LVH. Reduction of
      left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical
      outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in
      patients with high risk hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in left ventricular mass index after 52 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in left ventricular mass after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic function after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aorta function assessed blood pressure measurements after 52 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in markers of fibrosis and increased heart size after 52 weeks</measure>
  </secondary_outcome>
  <enrollment type="Actual">125</enrollment>
  <condition>Hypertension</condition>
  <condition>Left Ventricular Hypertrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/benazepril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or female patients â‰¥ 55 years of age

          -  LVH as confirmed by echocardiogram

          -  Patients with high risk hypertension, currently treated or already taking
             antihypertensive medication

        Exclusion Criteria:

          -  Renal artery stenosis

          -  Symptomatic heart failure or known ejection fraction &lt; 40%

          -  Myocardial infarction or stroke within 6 months

          -  Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers

          -  Pregnant or lactating females

          -  Cancer within the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2445</url>
    <description>Results for CCIB002FUS16 from the Novartis Clinical Trials website.</description>
  </link>
  <results_reference>
    <citation>Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B. Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension. 2009 Oct;54(4):731-7. doi: 10.1161/HYPERTENSIONAHA.109.130641. Epub 2009 Aug 17.</citation>
    <PMID>19687350</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <keyword>Hypertension</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

